LRIG3 and central nervous system cancer: Our recent study indicated that LRIG3 can suppress the growth of GBM cell lines and tumor xenografts in Cell line-derived xenograft model by downregulating the activity of MET/phosphatidylinositol 3-kinase/Akt signaling pathway, thus playing an anti-tumor role in glioma [17].